Product/Primary Packaging Featured Articles
-
New Guidelines Offer Menu Of Standard Sterile Packaging Tests
4/5/2016
A package protects the product throughout the life cycle, and package integrity is a significant pocket of risk that can be mitigated. Packaging integrity can literally be a matter of life or death.
-
Optimize Packaging For Different Dosage Forms
8/12/2015
There are thousands of drugs licensed for use in the UK as well as many different dosage forms. Packaging these quantities reliably calls for innovative machine technology and optimum process technology. An example is the high performance blister machine from Uhlmann, featuring the fastest cartoner in the world and sophisticated valve terminal technology.
-
Companies To Watch: StemCells
4/1/2013
StemCells has a cautious agenda in developing tissue-derived adult stem cell therapeutics that could lead to big leaps in patients’ quality of life.
-
Parenterals, Prefills, & Purity: Are Suppliers Up To The Challenge?
4/1/2013
With more reliance on large-molecule drugs, the injectables market has soared just as shortages due to product contamination, recalls and plant shutdowns have plagued companies and patients.
-
Anticounterfeiting With 2D Code: The Secret Is In The DNA
3/26/2013
Are current solutions enough to tackle the growing counterfeit problem?
-
Serialization Strategy 101
3/26/2013
A step-by-step guide to implement track and trace.
-
Cost Saving Benefits Of Deblistering Systems
12/17/2012
Sepha explains how you can save on cost and increase your production yield by providing answers to frequently asked questions about deblistering.
-
Considerations For Selecting Blister Packaging Materials For Pharmaceutical Products
12/17/2012
Sepha explains what needs to be taken into consideration when choosing the proper blister packaing forming and sealing materials.
-
Two Key Questions In Platform Injection Device Development
11/16/2012
In my last column, I explained that many pharma companies have adopted an approach to advanced injection devices based on using a glass primary syringe within a platform delivery system. This approach is based on two main premises. The first is that the stability of the drug in contact with glass will have been well characterized, as the product may well already have been launched in a prefilled syringe format.
-
Does Your CMO Have A Contingency Plan?
10/1/2012
Who is responsible for creating a contingency plan, you or your CMO? For pharmaceutical or biotech companies, a well thought contingency plan can mean the difference between life and death.